Home › Research › Treatments
Incorporating ethnicity into genetic risk assessment for Alzheimer disease: the REVEAL study experience
Christensen KD, Roberts JS, Royal CD, Fasaye GA, Obisesan T, Cupples LA, Whitehouse PJ, Butson MB et al.. Genetics in medicine : official journal of the American College of Medical Genetics, 2008-03-01
Topic: Amyloid, tau and blood-test diagnosis
Purpose To describe how investigators in a multisite randomized clinical trial addressed scientific and ethical issues involved in creating risk models based on genetic testing for African American participants. Methods The following informed our decision whether to stratify risk assessment by ethnicity: evaluation of epidemiological data, appraisal of benefits and risks of incorporating ethnicity into calculations, and feasibility of creating ethnicity-specific risk curves. Once the decision was made, risk curves were created based on data from a large, diverse study of first-degree relatives of patients with Alzheimer disease. Results Review of epidemiological data suggested notable differences in risk between African Americans and whites and that Apolipoprotein E genotype predicts risk in both groups. Discussions about the benefits and risks of stratified risk assessments reached consensus that estimates based on data from whites should not preclude enrolling African Americans, but population-specific risk curves should be created if feasible. Risk models specific to ethnicity, gender, and Apolipoprotein E genotype were subsequently developed for the randomized clinical trial that oversampled African Americans. Conclusion The Risk Evaluation and Education for Alzheimer Disease study provides an instructive example of a process to develop risk assessment protocols that are sensitive to the implications of genetic testing for multiple ethnic groups with differing levels of risk.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Christensen, K. D., Roberts, J. S., Royal, C. D., Fasaye, G. A., Obisesan, T., Cupples, L. A., et al. (2008). Incorporating ethnicity into genetic risk assessment for Alzheimer disease: the REVEAL study experience. Genetics in medicine : official journal of the American College of Medical Genetics. https://doi.org/10.1097/gim.0b013e318164e4cf
Vancouver
Christensen KD, Roberts JS, Royal CD, Fasaye GA, Obisesan T, Cupples LA, et al. Incorporating ethnicity into genetic risk assessment for Alzheimer disease: the REVEAL study experience. Genetics in medicine : official journal of the American College of Medical Genetics. 2008. doi:10.1097/gim.0b013e318164e4cf. PMID: 18344711.
BibTeX
@article{christensen2008-18344711,
author = {Christensen, K. D. and Roberts, J. S. and Royal, C. D. and Fasaye, G. A. and Obisesan, T. and Cupples, L. A. and Whitehouse, P. J. and Butson, M. B. and others},
title = {{Incorporating ethnicity into genetic risk assessment for Alzheimer disease: the REVEAL study experience}},
journal = {Genetics in medicine : official journal of the American College of Medical Genetics},
year = {2008},
doi = {10.1097/gim.0b013e318164e4cf},
pmid = {18344711},
url = {https://doi.org/10.1097/gim.0b013e318164e4cf}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Results Review of epidemiological data suggested notable differences in risk between African Americans and whites and that Apolipoprotein E genotype predicts risk in both groups.
Why it matters
This paper describes how investigators in a randomized clinical trial decided to create risk models based on genetic testing that were specific to ethnicity, gender, and Apolipoprotein E genotype. It addresses how risk assessment was designed for the study rather than testing a treatment to cure or prevent Alzheimer's disease.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthHigh
How this study scored 57/100
Published in a peer-reviewed journal, and it is a randomized controlled trial. Scored zero for sample size and effect reported because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Genetics in medicine : official journal of the American College of Medical Genetics) |
| Journal's citation record | 2 / 4 | Genetics in Medicine: journal h-index 204 (OpenAlex, 2026-10-29) |
| Study design | 11 / 12 | A randomized controlled trial (from PubMed type “Randomized Controlled Trial”) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2008 — within 20 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (pubmed indexes it as a clinical or observational study) |
| Randomized / blinded | 1 / 2 | Randomized (as stated in the record) |
| Times cited | 4 / 7 | Cited 42 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 2.1 citations a year over 20 year(s) since 2008 |
| Impact for its field and year | 2 / 6 | Cited 2.5× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 4 other studies in this library |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Robert C. Green: h-index 32 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University of Michigan: institution h-index 2,240 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 8 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 18344711) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 57 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1097/gim.0b013e318164e4cf
- PubMed: 18344711
- Original source →
- Free full text: PubMed Central →
Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
4 studies in the alzhub library list this one in their references.
Related studies in Treatments
Also in Treatments
192 studies in the library are filed under Treatments with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Treatments hub.